Spain gets rare Ebola drug to treat stricken priest
A Spanish priest has received one of the world's few doses of an experimental Ebola drug, raising ethical questions about how to allocate scarce medicines for a fatal disease at a time when the virus has infected at least 1,779 people in West Africa.
The drug, ZMapp, is a mixture of three antibodies engineered to recognize Ebola and bind to infected cells so the immune system can kill them. It hasn't been tested in humans.
ZMapp's maker, Mapp Biopharmaceutical of San Diego, has said “very little of the drug is currently available” and that it is cooperating with government agencies to increase production as quickly as possible. The drug takes several months to produce, meaning that it will be months before any would be available in large amounts. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said publicly that he knows of only three or four doses.
Two American aid workers who were infected with Ebola and flown from Africa to Atlanta have received doses.
Contrary to what many people believe, the “ultimate decision” for who gets an experimental drug is made by the manufacturer, not the government, said Arthur Caplan, head of the division of medical ethics at New York University's Langone Medical Center.
The World Health Organization scheduled a special meeting on Monday to discuss how to ration scarce doses of the drug, and is expected to release a statement on Tuesday. There are no proven medications or vaccines to treat Ebola, which has killed at least 961 people, although several therapies are in development.
Anthony Kamara, a 27-year-old man in Freetown, Sierra Leone, said, “Americans are very selfish. They only care about the lives of themselves and no one else.”
He referred to ZMapp as “the miracle serum” that the United States has “refused to share with us to save African lives.”
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Conviction overturned in Italy murder case for Seattle woman
- Antarctica yields life in extremist of conditions, so what about on another planet?
- Terror strikes Somalia hotel
- Nigerian President Jonathan urges peaceful vote as elections loom
- Israel to release tax funds held over Palestinian Authority’s move to join the ICC
- Airstrikes intensify in Yemen as Egypt, Saudis consider ground forces
- As Nemtsov buried, Russian opposition faces gloomy future
- Iran poses top threat to Mideast stability, Israeli consul general says
- U.S.-led coalition conducting surveillance flights over Tikrit
- France opens black box, hoping to unlock jet crash mystery
- Controversial bishop’s appointment in Chile riles pope’s panel